Roche Palo Alto LLC

Essential Therapeutics, Inc.

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Remy Lemoine

Michael Soth

Johannes Cornelius Hermann

Joe Timothy Bamberg

David Bernard Smith

Yan Lou

Aesop Cho

Timothy D Owens

Todd Richard Elworthy

Rama K Kondru

Robert Than Hendricks

Hanbiao Yang

Daisy Joe DuBois

William John Watkins

Eric Brian Sjogren

Javier De Vicente Fidalgo

Alam Jahangir

Allen John Lovey

Hongju Li

David Mark Rotstein

Calvin Wesley Yee

Daisy Joe Du Bois

Monica H Palme

Chris Richard Melville

Jutta Wanner

Jaehyeon Park

Thomas E Renau

Mark Bartlett

Will J Watkins

The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R', X, X&#x2032;, Y, Z, Z, and Zare defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

Inhibitors of JAK

The present invention relates to the use of novel pyrrolopyrazinyl urea derivatives of Formula I, wherein the variables R, R, R, R, and Rare defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

Pyrrolopyrazinyl urea kinase inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R, and X are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Pyrrolopyrazine kinase inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R-Rand Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I. 

Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists

This invention relates to compounds that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism.

Fungal efflux pump inhibitors

Growing community of inventors

San Francisco, CA, United States of America

Remy Lemoine